Essex Woodlands Management, Inc. - Q1 2022 holdings

$414 Million is the total value of Essex Woodlands Management, Inc.'s 9 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 10.0% .

 Value Shares↓ Weighting
BVS  BIOVENTUS$170,563,000
-2.7%
12,096,7020.0%41.24%
+4.6%
MDXG BuyMIMEDX GROUP, INC.$110,287,000
-21.9%
23,415,584
+0.2%
26.66%
-16.0%
EYPT  EYEPOINT PHARMACEUTICALS INC$50,920,000
-0.7%
4,190,9210.0%12.31%
+6.7%
TELA BuyTELA BIO, INC.$38,568,000
+58.1%
3,316,236
+74.0%
9.32%
+69.9%
VERO  VENUS CONCEPT, INC.$23,363,000
-15.9%
21,169,4570.0%5.65%
-9.6%
RVNC  REVANCE THERAPEUTICS INC$8,913,000
+19.5%
457,0850.0%2.16%
+28.4%
 SONENDO INC$7,990,000
-30.4%
1,992,5260.0%1.93%
-25.1%
MNOV  MEDICINOVA INC$2,953,000
-0.4%
1,105,9410.0%0.71%
+7.0%
CBIO  CATALYST BIOSCIENCES INC$52,000
-27.8%
78,6220.0%0.01%
-18.8%
AXGN ExitAXOGEN INC$0-296,416
-100.0%
-0.62%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2022-05-16
Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
MEDICINOVA INC42Q3 20236.5%
REVANCE THERAPEUTICS INC39Q3 202344.6%
AXOGEN INC26Q4 202143.3%
ENDOLOGIX INC24Q1 201922.5%
ABIOMED INC20Q1 201852.1%
CORIUM INTL INC20Q1 201923.5%
TELA BIO, INC.16Q3 202331.5%
VENUS CONCEPT, INC.16Q3 202321.3%
ACURA PHARMACEUTICALS INC15Q1 20191.4%
CATALYST BIOSCIENCES INC15Q1 20191.0%

View Essex Woodlands Management, Inc.'s complete holdings history.

Latest filings
TypeFiled
13F-HR2024-02-14
13F-HR2023-11-14
13F-HR2023-08-14
13F-HR2023-05-15
13F-HR2023-02-14
13F-HR2022-11-14
13F-HR2022-08-15
13F-HR2022-05-16
13F-HR2022-02-14
13F-HR2021-11-15

View Essex Woodlands Management, Inc.'s complete filings history.

Compare quarters

Export Essex Woodlands Management, Inc.'s holdings